Nausicalm (Dimenhydrinate)

Dimenhydrinate blocks histamine H1 receptors and has anticholinergic activity, which reduces stimulation of the vestibular system and the chemoreceptor trigger zone. This dual action lessens the brain’s response to motion and chemical signals that trigger nausea and vomiting.

The appropriate dose of Nausicalm is determined by the prescriber based on the patient’s age, weight, and clinical situation. Healthcare professionals set the regimen, and patients should follow the specific instructions provided on the prescription label.

Safety data for dimenhydrinate in pregnancy and lactation are limited. It should only be used if the potential benefit outweighs any possible risk, and this decision must be made by a qualified healthcare provider after evaluating the individual’s circumstances.

To request Nausicalm, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with second‑generation antihistamines or newer anti‑emetics such as ondansetron, dimenhydrinate is less selective and may cause more sedation and anticholinergic effects. However, it remains a cost‑effective, widely available option for mild to moderate motion‑related nausea.

Store Nausicalm at ambient temperature, below 25 °C, in its original container. Keep the product away from moisture, direct sunlight, and heat sources to maintain its stability and potency throughout its shelf life.

Nausicalm is taken orally, usually as a tablet, with or without food as directed by a healthcare professional. The tablet should be swallowed whole with a glass of water and not chewed or crushed unless specifically advised.

Serious risks include severe allergic reactions (rash, angioedema, anaphylaxis), rapid heart rate or arrhythmias, significant confusion or hallucinations, and urinary retention in susceptible individuals. Prompt medical attention is required if any of these symptoms occur.

Individuals with known hypersensitivity to dimenhydrinate or other first‑generation antihistamines should avoid Nausicalm. It is also contraindicated in patients with severe glaucoma, uncontrolled asthma, or certain cardiac conditions unless a physician determines that benefits outweigh risks.